β-CD, like apoA-I, is an acceptor for excess cellcholesterol (27); therefore, it is believed to be used as acholesterol-lowering medicine in some neurodegenerativedisease such as NPC to reduce cell overload cholesterol(19). This evidence concerns the gene APOA1 and nasopharyngeal carcinoma.